MedTrace Logo

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

NCT07235527 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2025-12-08

No results posted yet for this study

Summary

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Conditions

  • Age Related Macular Degeneration
  • Exudative Age-Related Macular Degeneration
  • Anti Vascular Endothelial Growth Factor

Interventions

DRUG

Aflibercept biosimilar (MY-1701P)

Patients receiving the aflibercept biosimilar MY-1701P (marketed as Yesafili®) as part of routine clinical care.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-20
Primary Completion
2026-06-20
Completion
2026-08-20
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07235527 on ClinicalTrials.gov